Home News Ear and Nose and Throat News Clinical Severity Staging System May Aid Tx Selection for Meniere Disease

Clinical Severity Staging System May Aid Tx Selection for Meniere Disease

Decreased vertigo severity, comorbidity burden, and absence of hearing loss tied to conservative treatment response

By Lori Solomon HealthDay Reporter

WEDNESDAY, Sept. 6, 2023 (HealthDay News) — A three-factor, composite clinical severity staging system can optimize treatment selection for the management of Meniere disease, according to a study published online Aug. 25 in Otolaryngology — Head and Neck Surgery.

Brevin J. Miller, from Washington University in St. Louis, and colleagues sought to identify clinically important factors associated with conservative treatment response in Meniere disease and to develop a composite clinical severity staging system. Seventy-eight patients were enrolled in the study.

The researchers found that 63 percent of patients were responsive to conservative therapies. Higher proportions of no or mild vertigo (24 percent) and none or mild comorbidity (27 percent) and a lower proportion of hearing loss (19 percent) were seen among responsive versus unresponsive patients. A three-stage system that consolidated these factors demonstrated a treatment response gradient ranging from 100 percent for stage 1 (11 patients), 64 percent for stage 2 (56 patients), and 18 percent for stage 3 (11 patients).

“A composite clinical severity staging system including these three factors can be used to optimize treatment selection and promote patient-centered management of Meniere’s disease,” the authors write.

One author reported being a consultant for Cochlear Ltd.

Abstract/Full Text (subscription or payment may be required)

Copyright © 2023 HealthDay. All rights reserved.